Oss, The Netherlands (PRWEB) January 24, 2006
Organon, the human healthcare business of Akzo Nobel, and Shanghai Genomics Inc, the China-based affiliate of GNI and one of China’s leading biotech companies, today announced an agreement to collaborate on a new research project. The collaboration, which will involve biological development work aimed at progressing Organon’s program for the identification of more selective steroid hormone receptor modulators, will initially last for a period of two years.
Shanghai Genomics, which in 2005 merged with GNI Ltd., the Asia-based global pharmaceutical company, will use its expertise in protein purification and cell-based interaction assays to clarify the clinical relevance of a number of receptor interacting proteins and their use in drug discovery. In particular, the research will focus upon the areas of rheumatoid arthritis, atherosclerosis and oncology.
“We are delighted to have successfully finalized this new research partnership with Shanghai Genomics as part of our research strategy to forge closer links with China’s highly skilled and motivated scientists. This is now the second major research collaboration deal that Organon has recently finalized in China,” said Dr David Nicholson, Executive Vice President Global Research, Organon International Inc. ”We are confident that Shanghai Genomics’ integrated drug discovery platform and their expertise in nuclear receptor biology will result in a successful project, in close collaboration with our own research scientists,” he added.
Ying Luo, President and CEO Shanghai Genomics, and President and COO of GNI said, “Shanghai Genomics is delighted to be collaborating with Organon on this exciting project. This is yet another validation of the model we have refined with GNI, where we are the first and the only company to combine innovative Western science with cost-efficient research capabilities in China, and access to the Chinese and Japanese pharmaceutical markets. Utilizing our highly efficient yet cost-effective technology platform we have entered into and completed numerous research based collaborations with international partners such as Organon, and we look forward to furthering our research efforts in these important areas.”
For more information, please contact:
Monique Mols, Director Media Relations, tel. +31-412-665440, email: monique.mols @ organon.com
Ying Luo, President and COO, tel. +86-21-50802786, email: yluo @ shanghaigenomics.com
Carol Cherkis, VP-Business Development, tel. +1-408-572-5567, email: firstname.lastname@example.org
Organon - with shared head offices in Roseland, NJ, USA and Oss, The Netherlands - creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: gynecology, fertility, neuroscience and anesthesia.
Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. http://www.organon.com
About Shanghai Genomics
Shanghai Genomics was founded in August 2001, by returned overseas biotech veterans, Drs. Ying Luo and Jun Wu, with funding from two Chinese venture capital funds ---Shanghai Venture Capital Company and Shanghai Zhangjiang Hi-Tech Park Corp. The company has won multiple research contracts and grants from the National Ministry of Science and Technology and Shanghai Municipal Government. In July 2005, Shanghai Genomics merged with GNI, a highly innovative Tokyo-headquartered, Asia-focused pharmaceutical company that is the global leader in the field of integrated systems pharmacology.
Using ethically approved methods, GNI has successfully mapped the gene regulatory networks via a complex process of reverse-engineering. Furthermore, GNI is the only company to have developed the technology required to apply this data to drug development and discovery. http://www.shanghaigenomics.com and http://www.gene-networks.com
Safe Harbor Statement*
This report contains statements which address such key issues as Organon’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the “Outlook,” should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.
For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company’s website http://www.akzonobel.com.
Pursuant to the U.S. Private Securities Litigation Reform Act 1995.